DK3059323T3 - DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS - Google Patents

DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS Download PDF

Info

Publication number: DK3059323T3
Authority: DK; Denmark
Prior art keywords: subject; osteoarthritis; allele; genotype; vol
Prior art date: 2008-05-02

Application number

DK15193948.5T

Other languages

Danish (da)

English (en)

Inventor

Jack F Bukowski

Nazneen Aziz

Hwa-Ying Wang

Kenneth Huttner

Steven B Abramson

Mukundan Attur

Original Assignee

Orig3N Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-02

Filing date

2009-05-04

Publication date

2019-03-04

2009-05-04 Application filed by Orig3N Inc filed Critical Orig3N Inc

2019-03-04 Application granted granted Critical

2019-03-04 Publication of DK3059323T3 publication Critical patent/DK3059323T3/en

Links

201000008482 osteoarthritis Diseases 0.000 title claims description 145
238000001514 detection method Methods 0.000 title claims description 35
230000002068 genetic effect Effects 0.000 title description 13
108700028369 Alleles Proteins 0.000 claims description 131
238000000034 method Methods 0.000 claims description 96
150000007523 nucleic acids Chemical class 0.000 claims description 49
102000039446 nucleic acids Human genes 0.000 claims description 45
108020004707 nucleic acids Proteins 0.000 claims description 45
206010061818 Disease progression Diseases 0.000 claims description 40
230000005750 disease progression Effects 0.000 claims description 40
108091034117 Oligonucleotide Proteins 0.000 claims description 33
230000003321 amplification Effects 0.000 claims description 28
238000003199 nucleic acid amplification method Methods 0.000 claims description 28
238000009396 hybridization Methods 0.000 claims description 19
238000004458 analytical method Methods 0.000 claims description 13
238000003556 assay Methods 0.000 claims description 12
102220134786 rs315952 Human genes 0.000 claims description 12
102220133450 rs419598 Human genes 0.000 claims description 12
102220134620 rs9005 Human genes 0.000 claims description 12
238000006243 chemical reaction Methods 0.000 claims description 8
238000012163 sequencing technique Methods 0.000 claims description 8
230000007717 exclusion Effects 0.000 claims description 4
101710163270 Nuclease Proteins 0.000 claims description 3
108010002352 Interleukin-1 Proteins 0.000 description 106
102000000589 Interleukin-1 Human genes 0.000 description 96
108090000623 proteins and genes Proteins 0.000 description 66
108020004414 DNA Proteins 0.000 description 61
102000053602 DNA Human genes 0.000 description 60
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 56
201000010099 disease Diseases 0.000 description 51
239000013615 primer Substances 0.000 description 37
239000000523 sample Substances 0.000 description 34
230000035772 mutation Effects 0.000 description 31
125000003729 nucleotide group Chemical group 0.000 description 30
102000054766 genetic haplotypes Human genes 0.000 description 28
239000002773 nucleotide Substances 0.000 description 27
238000003752 polymerase chain reaction Methods 0.000 description 25
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 22
241000219061 Rheum Species 0.000 description 18
210000004027 cell Anatomy 0.000 description 17
102000054765 polymorphisms of proteins Human genes 0.000 description 16
239000000047 product Substances 0.000 description 16
239000012634 fragment Substances 0.000 description 15
239000003814 drug Substances 0.000 description 14
239000003550 marker Substances 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
229920002477 rna polymer Polymers 0.000 description 14
206010003246 arthritis Diseases 0.000 description 13
239000013068 control sample Substances 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 10
108091008053 gene clusters Proteins 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
210000000845 cartilage Anatomy 0.000 description 9
210000000349 chromosome Anatomy 0.000 description 9
239000000463 material Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
102000003777 Interleukin-1 beta Human genes 0.000 description 8
108090000193 Interleukin-1 beta Proteins 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
229940079593 drug Drugs 0.000 description 8
210000003127 knee Anatomy 0.000 description 8
230000006798 recombination Effects 0.000 description 8
238000005215 recombination Methods 0.000 description 8
238000011285 therapeutic regimen Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000012408 PCR amplification Methods 0.000 description 7
210000001188 articular cartilage Anatomy 0.000 description 7
230000008901 benefit Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000002759 chromosomal effect Effects 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
239000013598 vector Substances 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 6
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 6
239000002253 acid Substances 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
210000001503 joint Anatomy 0.000 description 6
230000000770 proinflammatory effect Effects 0.000 description 6
230000007017 scission Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
230000014616 translation Effects 0.000 description 6
238000011282 treatment Methods 0.000 description 6
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 5
108060002716 Exonuclease Proteins 0.000 description 5
108050006617 Interleukin-1 receptor Proteins 0.000 description 5
230000007423 decrease Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
102000013165 exonuclease Human genes 0.000 description 5
238000013519 translation Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 4
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 4
102100020881 Interleukin-1 alpha Human genes 0.000 description 4
102100039065 Interleukin-1 beta Human genes 0.000 description 4
102000019223 Interleukin-1 receptor Human genes 0.000 description 4
208000003947 Knee Osteoarthritis Diseases 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
108700019146 Transgenes Proteins 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
-1 genomic Chemical class 0.000 description 4
210000003917 human chromosome Anatomy 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
239000003446 ligand Substances 0.000 description 4
238000007834 ligase chain reaction Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
229920000742 Cotton Polymers 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
239000003155 DNA primer Substances 0.000 description 3
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
108091093037 Peptide nucleic acid Proteins 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000032683 aging Effects 0.000 description 3
230000004075 alteration Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000007850 degeneration Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
238000003205 genotyping method Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
238000005070 sampling Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000002463 transducing effect Effects 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
208000019553 vascular disease Diseases 0.000 description 3
241000271566 Aves Species 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000032170 Congenital Abnormalities Diseases 0.000 description 2
108091027305 Heteroduplex Proteins 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000004927 clay Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000007799 cork Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000010448 genetic screening Methods 0.000 description 2
230000007614 genetic variation Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000033607 mismatch repair Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000007857 nested PCR Methods 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
239000012285 osmium tetroxide Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000003234 polygenic effect Effects 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000012521 purified sample Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
101150076141 rn gene Proteins 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
241001013596 Agestrata Species 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
108020001738 DNA Glycosylase Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000028381 DNA glycosylase Human genes 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
102220609134 Interleukin-1 alpha_A114S_mutation Human genes 0.000 description 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
206010061245 Internal injury Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000012807 PCR reagent Substances 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010010677 Phosphodiesterase I Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000225041 Roestes Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
206010048873 Traumatic arthritis Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000003491 array Methods 0.000 description 1
238000010420 art technique Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000010170 biological method Methods 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
230000037182 bone density Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000008355 cartilage degradation Effects 0.000 description 1
239000012707 chemical precursor Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
229960004590 diacerein Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
238000011979 disease modifying therapy Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000003268 heterogeneous phase assay Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003960 inflammatory cascade Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
102000002467 interleukin receptors Human genes 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000013150 knee replacement Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001459 lithography Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
238000007477 logistic regression Methods 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
101150029137 mutY gene Proteins 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
238000011330 nucleic acid test Methods 0.000 description 1
239000002417 nutraceutical Substances 0.000 description 1
235000021436 nutraceutical agent Nutrition 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000002987 primer (paints) Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
238000012175 pyrosequencing Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
108700015048 receptor decoy activity proteins Proteins 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229940089617 risedronate Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000013517 stratification Methods 0.000 description 1
210000005065 subchondral bone plate Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000011541 total hip replacement Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pathology (AREA)
Immunology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK15193948.5T 2008-05-02 2009-05-04 DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS DK3059323T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4999208P	2008-05-02	2008-05-02
US11874408P	2008-12-01	2008-12-01
EP09740020.4A EP2283156B1 (en)	2008-05-02	2009-05-04	Detecting genetic predisposition to osteoarthritis associated conditions

Publications (1)

Publication Number	Publication Date
DK3059323T3 true DK3059323T3 (en)	2019-03-04

Family

ID=41210581

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15193948.5T DK3059323T3 (en)	2008-05-02	2009-05-04	DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS
DK09740020.4T DK2283156T3 (en)	2008-05-02	2009-05-04	Detection of genetic predisposition to conditions associated with osteoarthritis

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK09740020.4T DK2283156T3 (en)	2008-05-02	2009-05-04	Detection of genetic predisposition to conditions associated with osteoarthritis

Country Status (9)

Country	Link
US (2)	US20100098775A1 (2)
EP (3)	EP3059323B1 (2)
JP (3)	JP5762282B2 (2)
AU (1)	AU2009242490B2 (2)
CA (1)	CA2723239C (2)
DK (2)	DK3059323T3 (2)
ES (2)	ES2561316T3 (2)
NZ (1)	NZ589034A (2)
WO (1)	WO2009135218A2 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5762282B2 (ja) *	2008-05-02	2015-08-12	インタールーキンジェネティクス，インコーポレイテッド	変形性関節症に関連する状態に対する遺伝的素因の検出
US20120115137A1 (en) *	2010-08-31	2012-05-10	Kornman Kenneth S	Methods of Predicting Osteoarthritis
CN104736723B (zh) *	2012-08-06	2017-10-31	默克专利有限公司	用于预测对fgf‑18化合物的响应性的遗传标记
AU2013301607B2 (en) *	2012-08-06	2018-10-18	Merck Patent Gmbh	Prognosis biomarkers in cartilage disorders
WO2017123696A1 (en)	2016-01-12	2017-07-20	Interleukin Genetics, Inc.	Methods for predicting response to treatment
US10337070B2 (en)	2017-01-12	2019-07-02	Cardioforecast Ltd.	Methods and kits for treating cardiovascular disease
IL273613B2 (en)	2017-09-29	2026-02-01	Merck Patent Gmbh	Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl)	2017-09-29	2022-08-31	Merck Patent Gmbh	Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) *	2018-09-10	2025-11-01	Merck Patent Gmbh	A method for reducing risk in a clinical trial
WO2020112853A1 (en)	2018-11-28	2020-06-04	Genascence Corporation	Methods and compositions for treating osteoarthritis
US20220249660A1 (en)	2019-06-06	2022-08-11	Sitokine Limited	Compositions and methods for treating lung, colorectal and breast cancer
EP4007819A4 (en) *	2019-08-02	2023-08-09	New York University	Methods and compositions for treating arthritis
WO2021028469A1 (en)	2019-08-12	2021-02-18	Sitokine Limited	Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en)	2020-04-09	2021-10-14	Sitokine Limited	Compositions and methods for treating covid-19

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8311018D0 (en)	1983-04-22	1983-05-25	Amersham Int Plc	Detecting mutations in dna
US4998617A (en) *	1986-09-15	1991-03-12	Laura Lupton Inc	Facial cosmetic liquid make up kit
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
US5459039A (en)	1989-05-12	1995-10-17	Duke University	Methods for mapping genetic mutations
FR2650840B1 (fr)	1989-08-11	1991-11-29	Bertin & Cie	Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en)	1991-03-05	1999-12-21	Molecular Tool, Inc.	Method for determining nucleotide identity through extension of immobilized primer
DE69433811T2 (de)	1993-01-07	2005-06-23	Sequenom, Inc., San Diego	Dns - sequenzierung durch massenspektronomie
US5593826A (en) *	1993-03-22	1997-01-14	Perkin-Elmer Corporation, Applied Biosystems, Inc.	Enzymatic ligation of 3'amino-substituted oligonucleotides
US5686246A (en) *	1995-08-03	1997-11-11	Kornman; Kenneth S.	Detecting genetic predisposition to periodontal disease
US5942390A (en)	1996-01-12	1999-08-24	Cedars-Sinai Medical Center	Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
US5698399A (en)	1996-04-05	1997-12-16	Duff; Gordon W.	Detecting genetic predisposition for osteoporosis
GB9621129D0 (en) *	1996-10-10	1996-11-27	Duff Gordon W	Detecting genetic predisposition to sight-threatening diabetic retinopathy
GB9706359D0 (en) *	1997-03-27	1997-05-14	Gemini International Holdings	Polymorphisms of an il-1 receptor antagonist gene
GB9711040D0 (en) *	1997-05-29	1997-07-23	Duff Gordon W	Prediction of inflammatory disease
WO2003064600A2 (en) *	2002-01-25	2003-08-07	Interleukin Genetics, Inc.	The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
WO2005056837A2 (en) *	2003-11-26	2005-06-23	Applera Corporation	Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
CA2631675A1 (en) *	2005-11-30	2007-06-21	The University Of North Carolina At Chapel Hill	Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
JP5762282B2 (ja) *	2008-05-02	2015-08-12	インタールーキンジェネティクス，インコーポレイテッド	変形性関節症に関連する状態に対する遺伝的素因の検出
US9037472B2 (en)	2012-04-20	2015-05-19	Nuance Communications, Inc.	Method and system for facilitating communications for a user transaction

2009
- 2009-05-04 JP JP2011507714A patent/JP5762282B2/ja active Active
- 2009-05-04 US US12/435,260 patent/US20100098775A1/en not_active Abandoned
- 2009-05-04 DK DK15193948.5T patent/DK3059323T3/en active
- 2009-05-04 EP EP15193948.5A patent/EP3059323B1/en not_active Not-in-force
- 2009-05-04 ES ES09740020.4T patent/ES2561316T3/es active Active
- 2009-05-04 EP EP18202413.3A patent/EP3467126A1/en not_active Withdrawn
- 2009-05-04 CA CA2723239A patent/CA2723239C/en active Active
- 2009-05-04 AU AU2009242490A patent/AU2009242490B2/en not_active Ceased
- 2009-05-04 DK DK09740020.4T patent/DK2283156T3/en active
- 2009-05-04 EP EP09740020.4A patent/EP2283156B1/en not_active Not-in-force
- 2009-05-04 NZ NZ589034A patent/NZ589034A/xx not_active IP Right Cessation
- 2009-05-04 ES ES15193948T patent/ES2708826T3/es active Active
- 2009-05-04 WO PCT/US2009/042746 patent/WO2009135218A2/en not_active Ceased
2015
- 2015-06-09 JP JP2015116397A patent/JP6263499B2/ja active Active
2016
- 2016-08-10 US US15/233,122 patent/US20160340734A1/en not_active Abandoned
2017
- 2017-12-18 JP JP2017241315A patent/JP2018038436A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP6263499B2 (ja)	2018-01-17
EP2283156B1 (en)	2015-11-11
WO2009135218A2 (en)	2009-11-05
JP5762282B2 (ja)	2015-08-12
JP2018038436A (ja)	2018-03-15
JP2011520433A (ja)	2011-07-21
US20100098775A1 (en)	2010-04-22
EP2283156A2 (en)	2011-02-16
ES2561316T3 (es)	2016-02-25
EP3059323B1 (en)	2018-12-12
ES2708826T3 (es)	2019-04-11
EP3059323A1 (en)	2016-08-24
DK2283156T3 (en)	2016-02-15
CA2723239A1 (en)	2009-11-05
JP2015211677A (ja)	2015-11-26
AU2009242490B2 (en)	2015-01-22
US20160340734A1 (en)	2016-11-24
AU2009242490A1 (en)	2009-11-05
CA2723239C (en)	2020-07-21
WO2009135218A3 (en)	2010-04-01
EP3467126A1 (en)	2019-04-10
NZ589034A (en)	2012-10-26

Publication	Publication Date	Title
DK3059323T3 (en)	2019-03-04	DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS
US20100129798A1 (en)	2010-05-27	Detecting genetic predisposition to osteoarthritis associated conditions
AU785040B2 (en)	2006-08-31	Diagnostics and therapeutics for osteoporosis
WO2001016377A9 (en)	2002-04-25	Diagnostics and therapeutics for osteoporosis
US20100028893A1 (en)	2010-02-04	Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases
AU2004263184B2 (en)	2010-12-02	Diagnostic and therapeutics for osteoporosis
US20090023147A1 (en)	2009-01-22	Diagnostics and therapeutics for osteoporosis
HK40012992A (en)	2020-08-07	Detecting genetic predisposition to osteoarthritis associated conditions
HK1225079B (en)	2020-01-24	Detecting genetic predisposition to osteoarthritis associated conditions
HK1225079A1 (en)	2017-09-01	Detecting genetic predisposition to osteoarthritis associated conditions
AU2015202038A1 (en)	2015-05-14	Detecting Genetic Predisposition To Osteoarthritis Associated Conditions
CA2308570A1 (en)	1999-05-20	Diagnostics and therapeutics for chronic obstructive airway disease
HK1093757B (en)	2011-07-08	Diagnostic for osteoporosis